Price$15.02+5.00 (+49.90%)
2026-03-172026-06-18
News · 26 weeks36+600%
2025-12-282026-06-21
Mix1390d
- Other7(54%)
- SEC Filings6(46%)
Latest news
25 items- SECSEC Form 424B5 filed by EUDA Health Holdings Limited424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by EUDA Health Holdings LimitedSCHEDULE 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- PREUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome MaskSINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask ("Regenixé Mask"), a beauty product developed by Chemokine Pte Ltd ("Chemokine"). EUDA holds the exclusive global distributorship rights for Helixé products, that includes but is not limited to, a next-generation immune health supplement, from Chemokine, a Singapore-based biotech company focused on molecular supplements and gene-modulating fo
- PREUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value DeficiencySingapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2). On May 28, 2026, the Company received a written notice from Nasdaq stating that the Company's Market Value of Listed Securities has b
- SECSEC Form F-3 filed by EUDA Health Holdings LimitedF-3 - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 20-F filed by EUDA Health Holdings Limited20-F - EUDA Health Holdings Ltd (0001847846) (Filer)
- PREUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy DevelopmentSINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. ("Shenzhen Inno"), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program. The Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial development. The approved project is scheduled to be implemented from January 1, 2026, to December 31, 2028, under the supervision of the Sh
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- PREUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed SecuritiesSingapore, April 27, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company") received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2). The MVLS Notice has no immediate effect on the listing of the Company's securities on Nasdaq and the Company has been provided a period of 180 calendar days from the date of the MVLS Notice, or until October 20, 2026, in which to regain co
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- PREUDA Announces Reverse Stock Split of its Ordinary SharesSINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it will implement a reverse stock split of its ordinary shares at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split was approved by the Company's Board of Directors in accordance with British Virgin Islands law. The Reverse Stock Split will take effect at market open on March 23, 2026, and the ordinary shares will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol "EUDA" and will con
- INSIDERSEC Form 3 filed by new insider Tay Whye Shin3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
- INSIDERSEC Form 3 filed by new insider Liew Kwong Yeow3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lew Chern Yong3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
- INSIDERSEC Form 3 filed by new insider Huang Bo3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- PREUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville WarrantSINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC. Background of the Warrant As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and Januar
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 424B5 filed by EUDA Health Holdings Limited424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 424B5 filed by EUDA Health Holdings Limited424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)
- SECSEC Form 6-K filed by EUDA Health Holdings Limited6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
EUDA FAQ
5 questionsWhere does EUDA stock trade?
EUDA Health Holdings Limited (EUDA) is listed on NASDAQ.What sector and industry is EUDA in?
EUDA Health Holdings Limited operates in the Health Care sector, Medical/Nursing Services industry.When did EUDA Health Holdings Limited go public?
EUDA Health Holdings Limited (EUDA) completed its IPO in 2021.What companies are similar to EUDA?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), HIMS (Hims & Hers Health Inc.), CHE (Chemed Corp), AMED (Amedisys Inc), LHCG (LHC Group). Compare EUDA side-by-side with any of them on Quantisnow.How can I track EUDA on Quantisnow?
Quantisnow aggregates EUDA Health Holdings Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EUDA to receive live email and push alerts on every new disclosure.